Topiramate attenuates withdrawal signs after chronic intermittent ethanol in rats
Topiramate attenuates withdrawal signs after chronic intermittent ethanol in rats
复制标题
DOI：
10.1097/00001756-200401190-00040
复制
发表时间：
2004-01-19
期刊：
影响因子：
1.7
通讯作者：
Olsen, RW
中科院分区：
文献类型：
--
作者：
Cagetti, E;Baicy, KJ;Olsen, RW
托吡酯是一种新型抗惊厥药物，具有中枢神经系统兴奋活性，包括增强GABA能抑制性突触传递。这种药理学谱的药物可能在减轻药物成瘾方面具有效用。本研究分析了TPM减少乙醇依赖点燃模型：慢性间歇性乙醇（CIE）大鼠戒断体征的能力。在CIE之后，持续的戒断症状表现为对惊厥药物戊四唑的癫痫易感性增加和在高架十字迷宫上测量的焦虑增加。托吡酯可显著提高CIE大鼠PTZ发作阈值，但对对照组无明显影响。在高架十字迷宫中，托吡酯对CIE大鼠的作用明显优于对照组。托吡酯可能对酒精戒断症状有治疗作用。
Topiramate, a novel anticonvulsant drug, has CNS depressant activity including enhancement of GABAergic inhibitory synaptic transmission. Drugs of this pharmacological spectrum might have utility in assuaging drug addiction. This study analyzes the ability of TPM to reduce withdrawal signs in the kindling model of ethanol dependence: chronic intermittent ethanol (CIE) rats. After CIE, persistent withdrawal signs are shown by an increased seizure susceptibility to the convulsant drug pentylenetetrazol and increased anxiety measured on the elevated plus-maze. Topiramate increased significantly the PTZ seizure threshold in CIE but not in control rats. On the elevated plus-maze, Topiramate was markedly more effective in CIE rats than in controls. Topiramate may have a therapeutic efficacy in treating alcohol withdrawal symptoms.